Methylafion stetus of RASSF1A and DAPK promoter in retinoblastoma

Chinese Journal of Ophthalmology

Volumn 45, Issue 7, 2009, Pages 631-635

  Ru, Liu ^a   Ling, Gao ^a   Guang Xiu, Lu ^a   Luo Sheng, Tang ^a   Xiao Hua, Zhu ^a   Jian, Wang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis regulatory proteins; Calcium calmodulin dependent protein kinases; Methylation; Promoter regions (genetics); Retinoblastoma; Tumor suppressor proteins

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE; DEATH-ASSOCIATED PROTEIN KINASE; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CASE CONTROL STUDY; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFANT; MALE; METABOLISM; METHYLATION; PRESCHOOL CHILD; PROMOTER REGION; RETINOBLASTOMA;

APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; METHYLATION; PROMOTER REGIONS, GENETIC; RETINOBLASTOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 68949086639     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: 10.3760/crna.j.issn.0412-4081.2009.07.011     Document Type: Article

References (25)

1. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet, 2003, 33:238-244.
2. Esteller M. CpG island hypermethylation and tumor suppress gene:a booming present, a brigher future. Oncogene, 2002, 21: 5427-5440.
3. Corson TW, Gallie B. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer, 2007, 46; 617-634.
4. Cohen Y, Shoham EM, Avraham RB, et al. Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Experimental Eye Research, 2008, 86;201-206.
5. Choy KW, Lee TC, Cheung KF, et al. Clinical Implications of Promoter Hypermethylation in RASSFIA and MGMT in Retinoblastomal. Neoplasia, 2005, 7:200-206.
6. David G, Burbee EF, Sabine ZM, et al. Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression. J Nat Cancer Inst, 2001, 93: 691-699.
7. Kong WJ, Zhang S, Guo CK, et al. Effect of methylation- associated silencing of death-associated protein kinase gene on nasopharyngeal carcinoma. Anticancer Drugs, 2006, 17; 251- 259.
8. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet, 2000, 25:315-319.
9. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSFIA from region 3p21. 3 in lung, breast and ovarian tumor. Oncogene, 2001, 20:1509-1518.
10. Chinese sources
11. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSFl A gene in pediatric tumors and cell lines. Oncogene, 2002, 21:4345-4349.
12. Choy KW, Lee TC, Cheung KF, et al. Clinical Implications of Promoter Hypermethylation in RASSFIA and MGMT in Retinoblastomal. Neoplasia, 2005, 7:200-206.
13. Joseph B, Mamatha C, Raman G, et al. Methylation status of RBI promoter in Indian retinoblastoma patients. Cancer Boil Ther, 2004,3:184-187.
14. Feinstein E, Druck T, Kastury K, et al. Assignment of DAP1 and DAPK-genes that positively mediate programmed cell death triggered by IFN-gamma~to chromosome regions 5pl2. 2 and 9q34.1, respectively. Genomics, 1995, 29:305-307.
15. Chim CS, Kwong YL.Fung TK. Methylation profiling in multiple myeloma. Leukemia Res,2004,28;379-385.
16. Tang X, Khuri FR, Lee J, et al. Hypermethylation of the death-associated protein kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst, 1992, 2: 1511-1516.
17. Uehara S.Taheuchi S.Tasaka T,et al. Aberrant methylation in promoter associated CpG is island of multiple genes in therapy related int. Oncol,2003,23:693-696.
18. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res, 2005, 11; 1219-1225.
19. Ibanez DC, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSFIA hypermethylation in serum, plasma, and peritoneal fluid ovarian cancer patients. Cancer Res, 2004, 64; 6476-6481.
20. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to chinicopathological features. Clin Cancer Res, 2002, 8:514-519.
21. Yang HJ, Liu SVW, Wang Y, et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol,2004, 93:435440.
22. Dulaimi E, Hillinck J, Ibanez de Caceres I, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res,2004,10:6189-6193.
23. Kiss S, Leiderman YI, Mukai S. Diagnosis, classification, and treatment of retinoblastoma. Int Ophthalmol Clin, 2008, 48; 135-147.
24. Mori T, O'Day SJ, Umetani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol, 2005, 23:9351-9358.
25. Koyanaqi K, Mori T, O'Day SJ, et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res, 2006, 66:6111-6117.